Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Apotex Withdraws 31 ANDAs After Failing To Ensure Data Integrity At Two Indian Manufacturing Plants

Jul 10 2019

• By Bowman Cox

withdrawn-stamp — data lapses eventually undermined approvals

Related Content

FDA Warns Apotex Management To Demand Quality, Meet Specs

Aug 17 2018

Manufacturing Compliance Updates In Brief From US FDA And EU

May 10 2018

FDA Advises Starting With the Lab When Sniffing Out Data Integrity

Dec 19 2014

In Brief: Seven drug import alerts, seven EU GMP findings, several particulates recalls

Apr 30 2014

News In Brief: Cheap American Drugs Replaced; EMA, FDA Differ on Toansa; Apotex Warned; Cheaper Drug Recalls

Jun 26 2014

Related Companies

Apotex Inc.

Additional Topics

United States India Asia Pacific Generic Drugs Quality Drug Approval Standards Manufacturing BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window